REVXF (Revenio Group Oyj) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

REVXF Revenio Group Oyj REVXF
82 GF Score
Price $16.41
GF Value $41.03
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Revenio Group Oyj FFO per Share?

FFO per Share only applies to REITs.

REVXF
82GF Score
Revenio Group Oyj REVXF
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Revenio Group Oyj (REVXF) Overvalued in 2026?

Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued. The current stock price of $16.41 is trading 60% below its estimated GF Value™ of $41.03. GuruFocus considers Revenio Group Oyj to be Significantly Undervalued.

Key valuation signals for REVXF:

  • FFO per Share:
  • GF Value™: $41.03 vs. price of $16.41 (60% below fair value)
  • GF Score™: 82/100 with 2 warning signs

No single metric tells the full story. See the REVXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Revenio Group Oyj Business Description

Address Harkahaankuja 7, Vantaa, FIN, 01730
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
82GF Score

Get the complete analysis for REVXF

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.41
Price
$41.03
GF Value